Currently, a phase I clinical trial of the first‐in‐class PTPN2/N1 inhibitor AC484 is in progress with advanced solid tumors (NCT04777994).[11] In this study, AC484 demonstrated a great anti‐tumor effect against ALK+ ALCL. This evidence concerns the gene ALK and anaplastic large cell lymphoma.